David Raiser

CEO and Co-Founder

David is head of strategy and business development at Aldatu. Prior to founding Aldatu, David worked in biotech and university technology transfer, and led a course on Healthcare Commercialization and Innovation at Harvard Medical School.

David hold Ph.D in Genetics from Harvard Medical School and holds a BS in Biology and BA in Music from the University of Richmond.

Iain MacLeod

CSO and Co-Founder

Iain is responsible for leading the advancement of Aldatu’s pathogen and drug resistance diagnostic technology in addition to guiding the company’s global health strategy. Iain maintains an academic appointment at the Harvard School of Public Health AIDS Initiative.

He undertook his post-doctoral training at the Harvard School of Public Health, and the Botswana-Harvard AIDS Institute in Gaborone, Botswana, where he focused on HIV drug resistance.

Iain holds a Ph.D. in Pathology – specializing in molecular virology – from the University of Cambridge (2008), an LL.M. in International Law, and a B.Sc. in Virology from the University of Glasgow.

Betsy Wonderly Trainor

VP Development

Betsy is responsible for commercialization strategy, NGO partnership strategy, and other development efforts.

Betsy has over 10 years of experience working in emerging markets, focusing on the validation and implementation of infectious disease diagnostics. Prior to Aldatu, Betsy was the VP of Business Development at Daktari Diagnostics, an HIV diagnostics company.  She also led the validation and implementation of Ebola diagnostics in West Africa on behaf of FIND (Foundation for Innovative New Diagnostics) in collaboration with the World Health Organization.

Betsy has a B.S in Human Development from Cornell University and is a graduate of the Product Management Program at Berkeley Haas School of Business.